Clinical Trial Update: Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS) [Phase 2]

View source ↗

Summary

Phase 2 study of DFV890 assessing safety, tolerability and efficacy in Familial Cold Autoinflammatory Syndrome completed; results posted May 3, 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Cold Autoinflammatory Syndrome

Drugs mentioned

• DFV890

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Familial Cold Autoinflammatory Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2024-05-03